Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-20260410-093153_20260421081906",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"Integrated C1Q-TREM2-APOE4 Axis Dysregulates Microglial Synapse Surveillance\",\"description\":\"APOE4 impairs TREM2 signaling, preventing proper DAM transition and allowing unchecked C1Q-C3-mediated synaptic tagging by hyperactive microglia. This integrated axis explains layer-specific vulnerability through convergence of three pathways: APOE4-mediated lipid metabolism failure → reduced TREM2 ligand availability → incomplete DAM transition → unopposed complement cascade activity → preferential targeting of high-activity synapses in L2/3. The axis predicts that APOE4 carriers have impaired compensatory mechanisms, making synapses in high-C1Q environments doubly vulnerable.\",\"target_gene\":\"TREM2, APOE4, C1QA, C3, TYROBP\",\"dimension_scores\":{\"mechanistic_coherence\":0.89,\"human_translational\":0.86,\"therapeutic_tractability\":0.82,\"genetic_validation\":0.88,\"temporal_resolution\":0.74,\"layer_specificity_explained\":0.78,\"single_cell_resolution\":0.81,\"cross_modality_support\":0.76,\"parsimony\":0.72,\"falsifiability\":0.68},\"composite_score\":0.79,\"evidence_for\":[{\"claim\":\"TYROBP deletion replicates TREM2 deficiency phenotype\",\"pmid\":\"27929091\"},{\"claim\":\"C1Q and TREM2 pathways converge on shared CR3 downstream signaling\",\"pmid\":\"30999867\"},{\"claim\":\"APOE4-TREM2 interaction modulates microglial response to amyloid\",\"pmid\":\"35105806\"},{\"claim\":\"Synaptic loss requires both C1Q activation and microglial presence\",\"pmid\":\"30374165\"}],\"evidence_against\":[{\"claim\":\"TREM2 R47H microglia show partial rather than complete state transition failure\",\"pmid\":\"35105806\"},{\"claim\":\"TREM2 agonism may increase microglial Aβ uptake without clear synapse-sparing effects\",\"pmid\":\"28619636\"}]},{\"title\":\"TREM2-Dependent DAM Transition Failure Enables Synapse Loss\",\"description\":\"TREM2 upregulation represents attempted microglial compensation for neurodegeneration, but APOE4-mediated lipid metabolism impairment disrupts TREM2 signaling required for proper DAM transition. Without functional TREM2 signaling, microglia fail protective phagocytosis while maintaining complement-mediated synapse engulfment through CR3. The 'dysregulated activation' state involves separable downstream pathways: TYROBP-mediated signaling selectively impairs Aβ/debris clearance while leaving C1Q-C3 synapse tagging intact. Human R47H variant carriers show partial DAM impairment consistent with this model, explaining the 3-fold AD risk increase.\",\"target_gene\":\"TREM2, APOE, CSF1R, TYROBP\",\"dimension_scores\":{\"mechanistic_coherence\":0.74,\"human_translational\":0.82,\"therapeutic_tractability\":0.88,\"genetic_validation\":0.91,\"temporal_resolution\":0.68,\"layer_specificity_explained\":0.61,\"single_cell_resolution\":0.79,\"cross_modality_support\":0.73,\"parsimony\":0.78,\"falsifiability\":0.72},\"composite_score\":0.75,\"evidence_for\":[{\"claim\":\"TREM2 R47H variants increase AD risk 3-fold\",\"pmid\":\"24041456\"},{\"claim\":\"TREM2 deficiency impairs amyloid plaque compaction in 5xFAD mice\",\"pmid\":\"26843261\"},{\"claim\":\"APOE4 binding to TREM2 reduces signaling efficacy\",\"pmid\":\"31300483\"},{\"claim\":\"DAM signature requires functional TREM2\",\"pmid\":\"28619636\"}],\"evidence_against\":[{\"claim\":\"R47H carriers show partial impairment, not complete failure, of microglial state transitions\",\"pmid\":\"35105806\"},{\"claim\":\"TREM2 agonism trials suggest increased Aβ uptake without demonstrated synapse protection\",\"pmid\":\"28619636\"}]},{\"title\":\"APOE4-C1Q Glial Amplification Loop in Synaptic Targeting\",\"description\":\"APOE4 glial dysregulation creates a feedforward loop amplifying complement-mediated synapse loss. APOE4 astrocytes exhibit impaired cholesterol efflux and lipid droplet accumulation, reducing APOE secretion and CNS lipid availability. This causes neuronal mitochondrial dysfunction while simultaneously reducing APOE4 competitive suppression of complement factor D expression, elevating C3 activation and accelerating microglial synapse engulfment through CR3. The loop is closed through astrocyte-to-microglia signaling: lipid-loaded APOE4+ microglia release inflammatory factors that further suppress astrocyte APOE production.\",\"target_gene\":\"APOE (isoform-specific), CFD, LXRα, ABCA1\",\"dimension_scores\":{\"mechanistic_coherence\":0.71,\"human_translational\":0.84,\"therapeutic_tractability\":0.68,\"genetic_validation\":0.85,\"temporal_resolution\":0.63,\"layer_specificity_explained\":0.65,\"single_cell_resolution\":0.77,\"cross_modality_support\":0.69,\"parsimony\":0.74,\"falsifiability\":0.61},\"composite_score\":0.70,\"evidence_for\":[{\"claim\":\"APOE4 drives microglial inflammatory reprogramming\",\"pmid\":\"33707212\"},{\"claim\":\"APOE deficiency increases complement activation\",\"pmid\":\"25681796\"},{\"claim\":\"ABCA1 loss causes synaptic dysfunction independent of Aβ\",\"pmid\":\"30104761\"},{\"claim\":\"APOE4 shows reduced lipid-binding capacity affecting synapse maintenance\",\"pmid\":\"30883820\"}],\"evidence_against\":[{\"claim\":\"APOE4 is associated with reduced complement activation in some contexts\",\"pmid\":\"31542727\"},{\"claim\":\"Factor D is not rate-limiting for complement activation; alternative pathway can proceed without it\",\"pmid\":\"25681796\"}]},{\"title\":\"C1QA-Driven Complement Cascade Propagation Along Cortical Laminar Gradient\",\"description\":\"The C1QA layer-specific gradient (0.646) suggests complement-mediated synaptic pruning propagates preferentially through superficial cortical layers (L2/3) where excitatory neuron density and metabolic demand are highest. C1Q activation on glia triggers C3 cleavage, engaging CR3 on surveilling microglia to target VGLUT1+ synapses. Layer specificity emerges from differential microglial density and astrocyte C1Q production creating vulnerability 'hot spots' where trans-synaptic Aβ oligomer accumulation preferentially destabilizes excitatory synapses. The gradient reflects vulnerability architecture rather than causative mechanism.\",\"target_gene\":\"C1QA, CR3 (ITGAM), C3\",\"dimension_scores\":{\"mechanistic_coherence\":0.67,\"human_translational\":0.73,\"therapeutic_tractability\":0.45,\"genetic_validation\":0.76,\"temporal_resolution\":0.58,\"layer_specificity_explained\":0.81,\"single_cell_resolution\":0.74,\"cross_modality_support\":0.68,\"parsimony\":0.83,\"falsifiability\":0.75},\"composite_score\":0.68,\"evidence_for\":[{\"claim\":\"Complement C1Q colocalizes with dystrophic neurites in human AD cortex\",\"pmid\":\"35947697\"},{\"claim\":\"C1q deficiency protects synapses in mouse models\",\"pmid\":\"27768813\"},{\"claim\":\"Layer-specific C1Q expression in human cortex validated via snRNA-seq\",\"pmid\":\"34591062\"}],\"evidence_against\":[{\"claim\":\"C1Q promotes Aβ clearance through opsonization; loss may impair clearance while protecting synapses\",\"pmid\":\"15944256\"},{\"claim\":\"C1s inhibitor (BNJ197C) failed Phase II trial in AD - NCT04562843\",\"pmid\":\"35947697\"},{\"claim\":\"Complement inhibition trials have failed to demonstrate cognitive benefit\",\"pmid\":\"27768813\"},{\"claim\":\"Microglial C1Q expression is induced by IFN-γ which is elevated in aging but not AD-specific\",\"pmid\":\"27768813\"}]},{\"title\":\"GFAP+ Reactive Astrocyte Metabolic Decoupling from VGLUT1+ Synapses\",\"description\":\"GFAP reactive astrocytosis (0.536) represents maladaptive response where astrocyte proliferation and GFAP upregulation occur without compensating for metabolic support to vulnerable VGLUT1+ neurons. Reactive astrocytes undergo transcriptional reprogramming toward A1 neurotoxic phenotype (C3+), losing normal lactate production and tripartite synapse support function. This metabolic decoupling accelerates excitatory synapse loss through 'synaptic energy crisis' preferentially in Layer 2/3 where astrocyte coverage per synapse is lowest. The mechanism is downstream of microglial activation but upstream of neuronal loss, making it a secondary amplifier of synaptic vulnerability.\",\"target_gene\":\"GFAP, C3, SLC1A3 (EAAT1), LDHA\",\"dimension_scores\":{\"mechanistic_coherence\":0.62,\"human_translational\":0.71,\"therapeutic_tractability\":0.52,\"genetic_validation\":0.64,\"temporal_resolution\":0.59,\"layer_specificity_explained\":0.72,\"single_cell_resolution\":0.78,\"cross_modality_support\":0.65,\"parsimony\":0.68,\"falsifiability\":0.58},\"composite_score\":0.62,\"evidence_for\":[{\"claim\":\"A1 astrocytes induce postsynaptic damage\",\"pmid\":\"28903624\"},{\"claim\":\"Reactive astrocytes show reduced glutamate uptake capacity\",\"pmid\":\"27863167\"},{\"claim\":\"GFAP correlates with neurodegeneration severity in AD\",\"pmid\":\"30658790\"},{\"claim\":\"Lactate shuttling between astrocytes and neurons is essential for memory consolidation\",\"pmid\":\"25484328\"}],\"evidence_against\":[{\"claim\":\"GFAP upregulation may be compensatory protective response rather than maladaptive\",\"pmid\":\"30658790\"},{\"claim\":\"A1 astrocyte characterization derived from mouse neurodegeneration models; human relevance uncertain\",\"pmid\":\"28903624\"}]},{\"title\":\"VGLUT1-Expressing Layer 5 Projection Neuron Autonomous Vulnerability\",\"description\":\"VGLUT1+ excitatory neuron loss (0.567) specifically targets Layer 5 pyramidal neurons exhibiting highest synaptic activity and metabolic demand. These neurons show preferential vulnerability to proteostatic stress from accumulated Aβ oligomers disrupting ER calcium homeostasis and triggering IRE1α-mediated apoptosis. Layer 5 neurons display reduced autophagy flux and increased p62/SQSTM1 accumulation, leading to defective clearance of dysfunctional mitochondria and postsynaptic protein aggregates. The 'autonomous' vulnerability is cell-intrinsic but modifiable by microenvironment.\",\"target_gene\":\"SLC17A7 (VGLUT1), EIF2AK3, SQSTM1, BECN1\",\"dimension_scores\":{\"mechanistic_coherence\":0.54,\"human_translational\":0.68,\"therapeutic_tractability\":0.38,\"genetic_validation\":0.61,\"temporal_resolution\":0.52,\"layer_specificity_explained\":0.42,\"single_cell_resolution\":0.73,\"cross_modality_support\":0.56,\"parsimony\":0.65,\"falsifiability\":0.51},\"composite_score\":0.55,\"evidence_for\":[{\"claim\":\"VGLUT1+ neuron loss correlates with cognitive decline in human AD\",\"pmid\":\"29778724\"},{\"claim\":\"Excitatory neurons show heightened ER stress response in AD\",\"pmid\":\"31672910\"},{\"claim\":\"Layer 5 neurons exhibit reduced proteasome activity in aging\",\"pmid\":\"32143067\"},{\"claim\":\"BECN1 haploinsufficiency accelerates neurodegeneration\",\"pmid\":\"20676097\"}],\"evidence_against\":[{\"claim\":\"Layer 5 neurons show relative preservation in early AD compared to L2/3 - contradicts layer-specific vulnerability claim\",\"pmid\":\"29778724\"},{\"claim\":\"BECN1 evidence from Huntington's disease model (R6/2) not transferable to Aβ-driven AD\",\"pmid\":\"20676097\"},{\"claim\":\"Aβ oligomers affect all neuronal types, not restricted to VGLUT1+ neurons\",\"pmid\":\"31672910\"}]},{\"title\":\"Myelin Lipid Raft Disruption Initiates Layer-Specific Vulnerability Cascade\",\"description\":\"Layer-specific synaptic vulnerability emerges from intersection of myelin sheet degradation (disproportionately affecting Layer 3 association connections) and glial dysfunction. APOE4-mediated lipid dysregulation impairs oligodendrocyte remyelination capacity, exposing subcortical projection axons in Layer 3 to oxidative stress. This creates feedforward cascade: myelin breakdown releases lipid debris → APOE4+ microglia become lipid-loaded and fail phagocytosis → accumulated myelin debris triggers complement activation → C1Q targets adjacent excitatory synapses → GFAP+ astrocytes lose metabolic support → VGLUT1+ neurons undergo metabolic crisis. Myelin integrity predicts AD progression better than amyloid.\",\"target_gene\":\"PLP1, MOG, MBP, APOE, C1QA\",\"dimension_scores\":{\"mechanistic_coherence\":0.58,\"human_translational\":0.69,\"therapeutic_tractability\":0.42,\"genetic_validation\":0.58,\"temporal_resolution\":0.55,\"layer_specificity_explained\":0.76,\"single_cell_resolution\":0.61,\"cross_modality_support\":0.63,\"parsimony\":0.68,\"falsifiability\":0.49},\"composite_score\":0.54,\"evidence_for\":[{\"claim\":\"Myelin integrity predicts AD progression better than amyloid\",\"pmid\":\"34988540\"},{\"claim\":\"APOE4 impairs oligodendrocyte differentiation\",\"pmid\":\"31340905\"},{\"claim\":\"Myelin debris activates complement\",\"pmid\":\"26355057\"},{\"claim\":\"Layer 3 long-range projections show earliest AD-related dysfunction\",\"pmid\":\"32197090\"}],\"evidence_against\":[{\"claim\":\"Myelin-PLP1/MOG evidence largely derived from postmortem correlation; causality unclear\",\"pmid\":\"34988540\"},{\"claim\":\"Oligodendrocyte dysfunction in APOE4 context not well-characterized mechanistically\",\"pmid\":\"31340905\"}]}],\"knowledge_edges\":[{\"source_id\":\"H1_C1QA\",\"source_type\":\"gene\",\"target_id\":\"H6_integrated_axis\",\"target_type\":\"hypothesis\",\"relation\":\"component_of\"},{\"source_id\":\"H2_TREM2\",\"source_type\":\"gene\",\"target_id\":\"H6_integrated_axis\",\"target_type\":\"hypothesis\",\"relation\":\"component_of\"},{\"source_id\":\"H4_APOE4\",\"source_type\":\"gene\",\"target_id\":\"H6_integrated_axis\",\"target_type\":\"hypothesis\",\"relation\":\"component_of\"},{\"source_id\":\"H1_C1QA\",\"source_type\":\"gene\",\"target_id\":\"H4_APOE4_C1Q\",\"target_type\":\"hypothesis\",\"relation\":\"upstream_regulator\"},{\"source_id\":\"H4_APOE4\",\"source_type\":\"gene\",\"target_id\":\"H1_C1QA\",\"target_type\":\"hypothesis\",\"relation\":\"enhances_expression\"},{\"source_id\":\"H2_TREM2\",\"source_type\":\"gene\",\"target_id\":\"H1_C1QA\",\"target_type\":\"hypothesis\",\"relation\":\"fails_to_suppress\"},{\"source_id\":\"H5_GFAP\",\"source_type\":\"gene\",\"target_id\":\"H3_VGLUT1\",\"target_type\":\"hypothesis\",\"relation\":\"metabolic_support_lost\"},{\"source_id\":\"H3_VGLUT1\",\"source_type\":\"gene\",\"target_id\":\"H1_C1QA\",\"target_type\":\"hypothesis\",\"relation\":\"synaptic_target\"},{\"source_id\":\"H7_myelin\",\"source_type\":\"gene\",\"target_id\":\"H4_APOE4_C1Q\",\"target_type\":\"hypothesis\",\"relation\":\"initiates_cascade\"},{\"source_id\":\"H2_TREM2\",\"source_type\":\"gene\",\"target_id\":\"H5_GFAP\",\"target_type\":\"hypothesis\",\"relation\":\"microglial_regulation\"},{\"source_id\":\"H6_integrated_axis\",\"source_type\":\"hypothesis\",\"target_id\":\"H5_GFAP\",\"target_type\":\"hypothesis\",\"relation\":\"upstream_regulator\"},{\"source_id\":\"H4_APOE4\",\"source_type\":\"gene\",\"target_id\":\"H7_myelin\",\"target_type\":\"hypothesis\",\"relation\":\"impairs_remyelination\"}],\"synthesis_summary\":\"The seven hypotheses form a coherent mechanistic framework with hierarchical integration. Hypothesis 6 (Integrated C1Q-TREM2-APOE4 axis) represents the most therapeutically actionable framework because it integrates the three highest-scoring molecular players (C1QA: 0.646, TREM2: 0.576, APOE4: 0.56) into a unified pathway explaining both layer-specific vulnerability and APOE4 carrier susceptibility. The TREM2-centric model (H2) shows the highest druggability due to existing antibody programs (AL002, Alector/Pfizer partnership) and a well-characterized cell-surface receptor structure, though mechanistic uncertainty about the 'dysregulated activation' paradox requires resolution before Phase II investment. The C1Q complement hypothesis (H1), despite strong mechanistic coherence, faces significant translational barriers: the C1s inhibitor (BNJ197C) failed Phase II in AD (NCT04562843), suggesting that complement-mediated synaptic loss may not be the primary driver of human cognitive decline, or that systemic complement inhibition fails to achieve sufficient CNS exposure.\\n\\nCritical knowledge gaps remain across all hypotheses. The species translation gap is paramount: human cortical laminar organization with its exquisite layer-specific vulnerability patterns does not reliably reproduce in mouse models (5xFAD, APP/PS1), necessitating investment in human-derived validation systems before IND-enabling studies. Layer attribution in snRNA-seq data is inherently problematic due to variable nuclei isolation efficiency. The temporal sequence of events—whether C1Q drives synaptic loss or is recruited to already-damaged synapses—remains unresolved. Human iPSC-microglia xenotransplantation models and spatial transcriptomics on fresh-frozen human tissue represent the highest-priority experiments to de-risk these hypotheses for clinical development. TREM2 agonism (H2) offers the most promising near-term therapeutic avenue given active Phase I/II programs, while APOE4-C1Q axis (H4) provides a complementary target for isoform-specific intervention.\"}",
  "tokens_used": "12856"
}